BioMérieux's molecular cancer diagnosis spinoff has agreed to a $230m purchase by women's health-focused Hologic.

Boston Scientific-backed pain cessation implant developer Neuros has secured $38m in a round co-led by Sectoral Asset Management and Amzak Health.

Dignity Health has exited OrthoSensor after the medical sensor technology provider was acquired by Stryker for an undiclosed sum.

Oxford Immunotec is set to return to private ownership in a $591m acquisition deal.

Leaps by Bayer led a round that also featured Amgen Ventures, Intel Capital and Alexandria Ventures Investments, taking the gene therapy technology developer's total funding to $158m.

IP Group portfolio company Hinge Health has pushed its valuation to $3bn following a $300m series D round co-led by Coatue Management and Tiger Global.

Existing investor Pasteur Mutualité came back for a round that will precede a trial of Volta's software, which helps in the treatment of cardiac arrythmias.

The antibody drug developer, majority owned by Luye Pharma, pushed its valuation past $850m in a round backed by Bank of China’s BOCG vehicle.

Eli Lilly invested directly and through its Lilly Asia Ventures fund, in a round that brought liver disease-focused drug developer Terns' overall funding to $197m.

The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.